Peptides
Evidence: animal_plus_anecdotal
Humanin is a 24-amino acid mitochondrial-derived peptide encoded by the 16S rRNA gene of mitochondrial DNA. It binds IGFBP-3 with high affinity (via Phe-6), interfering with IGFBP-3 binding to importin-beta and suppressing IGFBP-3-mediated apoptosis. It also inhibits the pro-apoptotic protein Bax (Bcl-2 family), preventing mitochondrial outer membrane permeabilization and intrinsic apoptosis. Humanin and IGFBP-3 synergistically protect neurons from amyloid-beta-induced apoptosis, and it activates the STAT3 and ERK1/2 pathways for cytoprotection.
Standard: Research indicates dosing remains experimental. Animal studies use 1-10 mcg/day equivalents. Human protocols are not established.
Administration: subcutaneousintravenous
Timing: No established timing protocol. Morning dosing suggested for neuroprotective applications.
Duration: Experimental — no established cycle lengths.
Humanin is part of the emerging mitochondrial-derived peptide (MDP) family alongside MOTS-c and SHMOTFLs. Circulating humanin levels decline with age, correlating with increased susceptibility to neurodegenerative disease. The anti-apoptotic mechanism is double-edged: neuroprotective but theoretically could support cancer cell survival. Humanin analogs (particularly S14G-Humanin/HNG) show enhanced potency and are more commonly used in research. This is a frontier compound — promising but with minimal human data. Best positioned for clients specifically interested in neuroprotection and longevity science.
Research-grade supplier only. Extremely limited availability. Synthetic humanin analogs (HNG, S14G-HN) may offer improved stability.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →